✦ LIBER ✦

Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis

✍ Scribed by Yuhki Yagi; Akira Andoh; Osamu Inatomi; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Keiichi Mitsuyama; Takashi Yoshida

Book ID: 106179921
Publisher: Springer Japan
Year: 2006
Tongue: English
Weight: 251 KB
Volume: 41
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-006-1797-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Suppression of interleukin-1β- and tumor

Suppression of interleukin-1β- and tumor necrosis factor-·-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

✍ Akira Andoh; Atsuhiro Ogawa; Ken-ichi Kitamura; Osamu Inatomi; Sanae Fujino; Tom 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 322 KB

Activated platelets as a possible early

Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients

✍ Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Ta 📂 Article 📅 2006 🏛 Springer Japan 🌐 English ⚖ 242 KB

Leukocytapheresis therapy for steroid-na

Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: Its clinical efficacy and adverse effects compared with those of conventional steroid therapy

✍ CHIHARU NISHIOKA; NOBUO AOYAMA; SHUJI MAEKAWA; DAISUKE SHIRASAKA; TAKAKO NAKAHAR 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Optimal apheresis treatment volume for t

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis

✍ Ken Fukunaga; Koji Kamikozuru; Yoko Yokoyama; Nobuyuki Hida; Yoshio Ohda; Naohis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

## Abstract **Background**: Leukocytapheresis (LCAP) is used as an adjunct therapy for patients with active ulcerative colitis (UC). Although, LCAP is routinely performed at 3,000 mL per session, we were interested to see that if this can be replaced with bodyweight (BW) adjusted volume. **Methods*

Mucosal healing in patients with ulcerat

Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: A prospective cohort study

✍ Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

Background: During active ulcerative colitis (UC), vast numbers of granulocytes, monocytes/macrophages (GM) infiltrate the mucosal tissue and can potentially exacerbate inflammation and injury. Accordingly, we were interested to see if selective depletion of GM by adsorption (GMA) impacts mucosal he

Outcomes after escalation of infliximab

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

✍ E. Rostholder; A. Ahmed; A. S. Cheifetz; A. C Moss 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB